Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-001005
Filing Date
2025-02-14
Accepted
2025-02-14 14:33:14
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8625
2 JOINT FILING AGREEMENT p25-0485exhibit99_1.htm EX-99.1 JOINT FILING 4427
  Complete submission text file 0000902664-25-001005.txt   15070
Mailing Address 6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN TX 78746
Business Address 6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN TX 78746 51285113796
Savara Inc (Subject) CIK: 0001160308 (see all company filings)

EIN.: 841318182 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-78541 | Film No.: 25626866
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 632 BROADWAY SUITE 602 NEW YORK NY 10012
Business Address 632 BROADWAY SUITE 602 NEW YORK NY 10012 6469894000
Vestal Point Capital, LP (Filed by) CIK: 0001974915 (see all company filings)

EIN.: 922296021 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G